Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: macromolecular drug conjugates - Prolynx

Next Previous
Search
Drug Profile

Research programme: macromolecular drug conjugates - Prolynx

Alternative Names: Dual receptor agonists - Prolynx; Hydrogel-exenatide - Prolynx; Hydrogel-octreotide - Prolynx; PEG-exenatide - Prolynx; PEG-octreotide - Prolynx; PLX 039

Latest Information Update: 28 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prolynx
  • Class Camptothecins; Drug conjugates; Polyethylene glycols
  • Mechanism of Action DNA topoisomerase I inhibitors; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Cancer; Type 2 diabetes mellitus

Highest Development Phases

  • No development reported Acromegaly; Cancer; Ear disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 28 Oct 2021 No recent reports of development identified for research development in Non-alcoholic-fatty-liver-disease in USA (SC, Injection)
  • 28 Oct 2021 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA (SC, Injection)
  • 28 Jul 2021 No recent reports of development identified for preclinical development in Obesity in USA (SC, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top